Welcome to our dedicated page for Livanova news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova stock.
LivaNova PLC reports developments as a global medical technology company focused on selected neurological and cardiac conditions. Company news commonly covers revenue results and guidance, performance in its Cardiopulmonary and Epilepsy businesses, and updates tied to medical-device commercialization and clinical evidence.
Recurring product themes include VNS Therapy for drug-resistant epilepsy, real-world evidence from the CORE-VNS study, and obstructive sleep apnea technology using proximal hypoglossal nerve stimulation. Updates also include FDA regulatory decisions, including premarket approval for the aura6000 System, investor conference appearances, and business update calls.
LivaNova (Nasdaq: LIVN) reported second-quarter 2026 revenue of $390.6 million, up 10.8% reported and 9.8% on a constant-currency basis versus 2025. Cardiopulmonary revenue rose 11.2% and Neuromodulation 10.1%. U.S. GAAP diluted EPS was $1.93, with adjusted diluted EPS of $1.26. Operating cash flow was $66.6 million and adjusted free cash flow $45.5 million.
The company raised 2026 guidance, now expecting constant-currency revenue growth of 8–9% and adjusted EPS of $4.30–$4.40, while lowering adjusted free cash flow guidance to $140–$160 million to fund strategic investments. LivaNova entered a long-term supply agreement with Thermo Fisher Scientific to increase availability of a critical oxygenator component and reported an €81.8 million ($95.4 million) discrete tax benefit from a favorable Italian tax ruling related to the SNIA environmental liability. The company also highlighted positive data for its PolySync programming algorithm in Obstructive Sleep Apnea and announced several senior leadership appointments.
LivaNova (Nasdaq: LIVN) will host a conference call to discuss its Q2 2026 results on Wednesday, August 5, 2026, at 1 p.m. London time (8 a.m. EDT).
The company will release results before the call, with live audiocast and replay available on its website.
LivaNova (Nasdaq: LIVN) reported new OSPREY substudy data showing its PolySync programming algorithm raised the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in moderate to severe Obstructive Sleep Apnea treated with proximal hypoglossal nerve stimulation (pHGNS).
Reprogramming non-responders with simultaneous-contact stimulation converted most into responders, improved AHI and oxygen desaturation index, and showed no serious treatment-emergent or device-related adverse events. LivaNova plans a PMA supplement for its next-generation, MRI-compatible, rechargeable OSA device in the second half of 2026.
LivaNova (Nasdaq: LIVN) elected Jette Nygaard-Andersen to its Board of Directors following the June 10 Annual General Meeting. She brings more than 25 years of leadership in regulated international businesses, including roles at Coloplast, Entain and Modern Times Group.
Dr. Sharon O’Kane stepped down after a decade on the Board. Committee leadership changes include Brooke Story as Chair of the Nominating and Corporate Governance Committee and Peter Wilver as Chair of the Compensation and Human Capital Management Committee, while William Kozy remains Board Chair.
LivaNova (Nasdaq: LIVN) appointed Anne Liddy as Chief Legal Officer, effective August 31. She will lead the global legal and compliance function and join the Executive Leadership Team.
Liddy brings over 20 years of healthcare and life sciences legal experience, including senior roles at Hologic, Pfizer, and Ropes & Gray.
LivaNova (Nasdaq: LIVN) appointed Stefano Folli as incoming President, Cardiopulmonary, effective June 1, 2026, succeeding Franco Poletti, who retires July 31.
Folli joins the Executive Leadership Team, reporting to the CEO, and will oversee strategic growth of the nearly $800 million Cardiopulmonary business.
LivaNova (Nasdaq: LIVN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach on June 8, 2026, at 8:00 a.m. EDT. A live webcast and replay will be accessible via the LivaNova events webpage.
LivaNova (Nasdaq: LIVN) reported Q1 2026 revenue of $362.3M, up 14.3% reported and 11.1% constant-currency, with GAAP diluted EPS of $0.40 and adjusted diluted EPS of $0.98. The company raised full-year 2026 constant-currency revenue growth guidance to 7.0%–8.0% and adjusted diluted EPS to $4.20–$4.30. LivaNova received FDA PMA for the aura6000 System for moderate to severe obstructive sleep apnea and published 12‑month OSPREY trial results showing sustained pHGNS benefits.
LivaNova (Nasdaq: LIVN) reported 12-month OSPREY RCT results showing proximal hypoglossal nerve stimulation (pHGNS) produced clinically significant, durable improvements in obstructive sleep apnea (OSA).
In 104 adults, median AHI fell from 34.3 to 11.6 e/hr at month 7; ODI median dropped from 35 to 13 e/hr. FDA PMA for the aura6000 System was granted in March; commercial launch expected in 2027 pending a PMA supplement.
LivaNova (Nasdaq: LIVN) will release its first-quarter 2026 results and host a conference call on Wed., May 6, 2026 at 1:00 p.m. London time (8:00 a.m. EDT). The company will publish results before the call.
Investors can access an audiocast at www.livanova.com/events, join by phone using the listed U.S. and international numbers, or listen to a replay on the Investors section immediately after the event. Log on ~10 minutes early for setup. Conference access code: 946097.